{"count": 7, "results": [{"_id": "33569418", "pmid": 33569418, "pmcid": "PMC7867894", "title": "Oral atenolol treatment for infantile hemangiomas: clinical analysis of 133 consecutive patients", "journal": "Ann Transl Med", "authors": ["Zhao ZL", "Liu C", "Wang QZ", "Wu HW", "Zheng JW"], "date": "2021-01-01T00:00:00Z", "doi": "10.21037/atm-20-5359", "meta_date_publication": "2021 Jan", "meta_volume": "9", "meta_issue": "2", "meta_pages": "116", "score": 50253.52, "text_hl": "No life-threatening complications were noted during and after oral @<m>CHEMICAL_Atenolol</m> @CHEMICAL_MESH:D001262 @@@atenolol@@@. Only 4 (3.0%) of 133 @SPECIES_9606 @@@patients@@@ developed minor complications including @<m>DISEASE_Diarrhea</m> @DISEASE_MESH:D003967 @@@diarrhea@@@. ", "citations": {"NLM": "Zhao ZL, Liu C, Wang QZ, Wu HW, Zheng JW. Oral atenolol treatment for infantile hemangiomas: clinical analysis of 133 consecutive patients Ann Transl Med. 2021 Jan;9(2):116. PMID: 33569418", "BibTeX": "@article{33569418, title={Oral atenolol treatment for infantile hemangiomas: clinical analysis of 133 consecutive patients}, author={Zhao ZL and Liu C and Wang QZ and Wu HW and Zheng JW}, journal={Ann Transl Med}, volume={9}, number={2}, pages={116}}"}}, {"_id": "27310994", "pmid": 27310994, "pmcid": "PMC4998480", "title": "Oral atenolol therapy for proliferating infantile hemangioma", "journal": "Medicine (Baltimore)", "authors": ["Ji Y", "Wang Q", "Chen S", "Xiang B", "Xu Z", "Li Y", "Zhong L", "Jiang X", "Yang X"], "date": "2016-06-01T00:00:00Z", "doi": "10.1097/MD.0000000000003908", "meta_date_publication": "2016 Jun", "meta_volume": "95", "meta_issue": "24", "meta_pages": "e3908", "score": 50068.21, "text_hl": "The most common event, @<m>DISEASE_Diarrhea</m> @DISEASE_MESH:D003967 @@@diarrhea@@@, was the main reason for temporarily discontinuing @<m>CHEMICAL_Atenolol</m> @CHEMICAL_MESH:D001262 @@@atenolol@@@. ", "citations": {"NLM": "Ji Y, Wang Q, Chen S, Xiang B, Xu Z, Li Y, Zhong L, Jiang X, Yang X. Oral atenolol therapy for proliferating infantile hemangioma Medicine (Baltimore). 2016 Jun;95(24):e3908. PMID: 27310994", "BibTeX": "@article{27310994, title={Oral atenolol therapy for proliferating infantile hemangioma}, author={Ji Y and Wang Q and Chen S and Xiang B and Xu Z and Li Y and Zhong L and Jiang X and Yang X}, journal={Medicine (Baltimore)}, volume={95}, number={24}, pages={e3908}}"}}, {"_id": "3250317", "pmid": 3250317, "title": "No difference in general well-being during antihypertensive treatment with atenolol or metoprolol CR.", "journal": "Ann Clin Res", "authors": ["Dahlöf C", "Almkvist G", "Dimenäs E", "Jern S", "Johansson B", "Larsson C", "Lorentzon S", "Nilsson D", "Nygaard-Pedersen L"], "date": "1988-01-01T00:00:00Z", "meta_date_publication": "1988", "meta_volume": "20 Suppl 48", "meta_issue": "", "meta_pages": "42-50", "score": 50058.22, "text_hl": "Other subjective symptoms (e.g. @<m>DISEASE_Diarrhea</m> @DISEASE_MESH:D003967 @@@diarrhoea@@@, @DISEASE_Bradycardia @DISEASE_MESH:D001919 @@@bradycardia@@@, cold hands and feet) were uncommon and equally distributed among @<m>CHEMICAL_Atenolol</m> @CHEMICAL_MESH:D001262 @@@atenolol@@@ and @CHEMICAL_Metoprolol @CHEMICAL_MESH:D008790 @@@metoprolol@@@ @SPECIES_9606 @@@patients@@@. 31 of the @SPECIES_9606 @@@patients@@@ preferred @CHEMICAL_Metoprolol @CHEMICAL_MESH:D008790 @@@metoprolol@@@ CR, 23 @<m>CHEMICAL_Atenolol</m> @CHEMICAL_MESH:D001262 @@@atenolol@@@, while 20 had no preference.", "citations": {"NLM": "Dahlöf C, Almkvist G, Dimenäs E, Jern S, Johansson B, Larsson C, Lorentzon S, Nilsson D, Nygaard-Pedersen L. No difference in general well-being during antihypertensive treatment with atenolol or metoprolol CR. Ann Clin Res. 1988;20 Suppl 48():42-50. PMID: 3250317", "BibTeX": "@article{3250317, title={No difference in general well-being during antihypertensive treatment with atenolol or metoprolol CR.}, author={Dahlöf C and Almkvist G and Dimenäs E and Jern S and Johansson B and Larsson C and Lorentzon S and Nilsson D and Nygaard-Pedersen L}, journal={Ann Clin Res}, volume={20 Suppl 48}, pages={42-50}}"}}, {"_id": "2894883", "pmid": 2894883, "title": "Nifedipine and atenolol singly and combined for treatment of essential hypertension: comparative multicentre study in general practice in the United Kingdom. Nifedipine-Atenolol Study Review Committee.", "journal": "Br Med J (Clin Res Ed)", "authors": ["Nifedipine-Atenolol Study Review Committee"], "date": "1988-02-13T00:00:00Z", "meta_date_publication": "1988 Feb 13", "meta_volume": "296", "meta_issue": "6620", "meta_pages": "468-72", "score": 50056.33, "text_hl": "Twenty six @SPECIES_9606 @@@patients@@@ (12%) were withdrawn because of adverse effects while taking @CHEMICAL_Nifedipine @CHEMICAL_MESH:D009543 @@@nifedipine@@@ compared with 19 (10%) taking @<m>CHEMICAL_Atenolol</m> @CHEMICAL_MESH:D001262 @@@atenolol@@@. @DISEASE_Flushing @DISEASE_MESH:D005483 @@@Flushing@@@ and @DISEASE_Tang_Hsi_Ryu_syndrome @DISEASE_MESH:C536897 @@@oedema@@@ were more common after the calcium antagonist, whereas @<m>DISEASE_Diarrhea</m> @DISEASE_MESH:D003967 @@@diarrhoea@@@ and @DISEASE_Dyspepsia @DISEASE_MESH:D004415 @@@dyspepsia@@@ were more common after @<m>CHEMICAL_Atenolol</m> @CHEMICAL_MESH:D001262 @@@atenolol@@@. ", "citations": {"NLM": "Nifedipine-Atenolol Study Review Committee. Nifedipine and atenolol singly and combined for treatment of essential hypertension: comparative multicentre study in general practice in the United Kingdom. Nifedipine-Atenolol Study Review Committee. Br Med J (Clin Res Ed). 1988 Feb 13;296(6620):468-72. PMID: 2894883", "BibTeX": "@article{2894883, title={Nifedipine and atenolol singly and combined for treatment of essential hypertension: comparative multicentre study in general practice in the United Kingdom. Nifedipine-Atenolol Study Review Committee.}, author={Nifedipine-Atenolol Study Review Committee}, journal={Br Med J (Clin Res Ed)}, volume={296}, number={6620}, pages={468-72}}"}}, {"_id": "2248757", "pmid": 2248757, "title": "Haemodynamic effects of bopindolol and atenolol in coronary artery disease. A noninvasive study.", "journal": "Ann Med", "authors": ["Rapola JM", "Pellinen TJ", "Toivonen L", "Nieminen MS"], "date": "1990-01-01T00:00:00Z", "doi": "10.3109/07853899009148929", "meta_date_publication": "1990", "meta_volume": "22", "meta_issue": "4", "meta_pages": "221-4", "score": 50053.574, "text_hl": "Two @SPECIES_9606 @@@patients@@@ on @CHEMICAL_bopindolol @CHEMICAL_MESH:C036007 @@@bopindolol@@@ left the study because of worsening symptoms of @DISEASE_Coronary_Artery_Disease @DISEASE_MESH:D003324 @@@coronary artery disease@@@, and two on @<m>CHEMICAL_Atenolol</m> @CHEMICAL_MESH:D001262 @@@atenolol@@@ owing to side effects, @DISEASE_Bradycardia @DISEASE_MESH:D001919 @@@bradycardia@@@ and @DISEASE_Syncope @DISEASE_MESH:D013575 @@@syncope@@@ in one and @<m>DISEASE_Diarrhea</m> @DISEASE_MESH:D003967 @@@diarrhea@@@ in the other. ", "citations": {"NLM": "Rapola JM, Pellinen TJ, Toivonen L, Nieminen MS. Haemodynamic effects of bopindolol and atenolol in coronary artery disease. A noninvasive study. Ann Med. 1990;22(4):221-4. PMID: 2248757", "BibTeX": "@article{2248757, title={Haemodynamic effects of bopindolol and atenolol in coronary artery disease. A noninvasive study.}, author={Rapola JM and Pellinen TJ and Toivonen L and Nieminen MS}, journal={Ann Med}, volume={22}, number={4}, pages={221-4}}"}}, {"_id": "26996370", "pmid": 26996370, "title": "Synthesis, Characterization, and Atenolol Delivery Application of Functionalized Mesoporous Hydroxyapatite Nanoparticles Prepared by Microwave-Assisted Co-precipitation Method.", "journal": "Curr Drug Deliv", "authors": ["Mortazavi-Derazkola S", "Naimi-Jamal MR", "Ghoreishi SM"], "date": "2016-01-01T00:00:00Z", "doi": "10.2174/1567201813666160321115543", "meta_date_publication": "2016", "meta_volume": "13", "meta_issue": "7", "meta_pages": "1123-1129", "score": 50052.734, "text_hl": "The synthesized material was used for storage/slow release study of @<m>CHEMICAL_Atenolol</m> @CHEMICAL_MESH:D001262 @@@atenolol@@@. RESULTS: @<m>CHEMICAL_Atenolol</m> @CHEMICAL_MESH:D001262 @@@Atenolol@@@ loaded mHAp shows immediate release of @<m>CHEMICAL_Atenolol</m> @CHEMICAL_MESH:D001262 @@@atenolol@@@ in pH 8, whileafter functionalizing shows up to ca. 30% release at the beginning. ", "citations": {"NLM": "Mortazavi-Derazkola S, Naimi-Jamal MR, Ghoreishi SM. Synthesis, Characterization, and Atenolol Delivery Application of Functionalized Mesoporous Hydroxyapatite Nanoparticles Prepared by Microwave-Assisted Co-precipitation Method. Curr Drug Deliv. 2016;13(7):1123-1129. PMID: 26996370", "BibTeX": "@article{26996370, title={Synthesis, Characterization, and Atenolol Delivery Application of Functionalized Mesoporous Hydroxyapatite Nanoparticles Prepared by Microwave-Assisted Co-precipitation Method.}, author={Mortazavi-Derazkola S and Naimi-Jamal MR and Ghoreishi SM}, journal={Curr Drug Deliv}, volume={13}, number={7}, pages={1123-1129}}"}}, {"_id": "8179835", "pmid": 8179835, "pmcid": "PMC3053877", "title": "Hyperkalemia due to hyporeninemic hypoaldosteronism with liver cirrhosis and hypertension.", "journal": "J Korean Med Sci", "authors": ["Kee CS", "Choi JW", "Chang DK", "Ahn YH", "Kim HJ"], "date": "1993-12-01T00:00:00Z", "doi": "10.3346/jkms.1993.8.6.464", "meta_date_publication": "1993 Dec", "meta_volume": "8", "meta_issue": "6", "meta_pages": "464-70", "score": 50034.637, "text_hl": "A 49-year-old man with @DISEASE_Liver_Cirrhosis @DISEASE_MESH:D008103 @@@liver cirrhosis@@@ and @DISEASE_Hypertension @DISEASE_MESH:D006973 @@@hypertension@@@ was found to have @DISEASE_Hyperkalemia @DISEASE_MESH:D006947 @@@hyperkalemia@@@ out of a degree of @DISEASE_Renal_Insufficiency @DISEASE_MESH:D051437 @@@renal insufficiency@@@ and @DISEASE_Acidosis @DISEASE_MESH:D000138 @@@metabolic acidosis@@@ with low to normal anion gap, aggravated by @DISEASE_Crisponi_syndrome @DISEASE_MESH:C536214 @@@volume contraction@@@ with @<m>DISEASE_Diarrhea</m> @DISEASE_MESH:D003967 @@@diarrhea@@@ and medications (@CHEMICAL_Captopril @CHEMICAL_MESH:D002216 @@@captopril@@@, @CHEMICAL_Spironolactone @CHEMICAL_MESH:D013148 @@@spironolactone@@@ and @<m>CHEMICAL_Atenolol</m> @CHEMICAL_MESH:D001262 @@@atenolol@@@) interfering with @CHEMICAL_Potassium @CHEMICAL_MESH:D011188 @@@potassium@@@ homeostasis. ", "citations": {"NLM": "Kee CS, Choi JW, Chang DK, Ahn YH, Kim HJ. Hyperkalemia due to hyporeninemic hypoaldosteronism with liver cirrhosis and hypertension. J Korean Med Sci. 1993 Dec;8(6):464-70. PMID: 8179835", "BibTeX": "@article{8179835, title={Hyperkalemia due to hyporeninemic hypoaldosteronism with liver cirrhosis and hypertension.}, author={Kee CS and Choi JW and Chang DK and Ahn YH and Kim HJ}, journal={J Korean Med Sci}, volume={8}, number={6}, pages={464-70}}"}}]}